Anti-RAGE Monoclonal for Research (Technology RFT-432b)
Scientists at NDSU have developed a monoclonal antibody that inhibits activation of the receptor for advanced glycation end products (RAGE) by blocking the V-domain. The V-domain binds multiple ligands that elicit sustained inflammation associated with diabetes, cancer, Alzheimer’s, multiple sclerosis, and other diseases. As a result, this monoclonal has value in research related to a wide variety of diseases. This antibody is available via non-exclusive license for research use only. Illustration and antibody specification figures are shown below.
PCT/US2015/047478 was filed August 28, 2015, and will publish on February 28, 2016. The antibody has been non-exclusively licensed to multiple licensees for research purposes.
Henry Nowak, Technology Manager
RFT, 432, RFT432
Inquire about this technology >